Skip to content
value.today

RIB X Pharmaceuticals Inc.

Total raised
$30 M
3 rounds on record
Latest round
$19 M
Nov 2012
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of RIB X Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2012$19 MNo. 3$10 to $50 million

RIB X Pharmaceuticals Inc.: Raise no. 3, Nov 2012

Investors in this round

4 investors had bought by the notice of Nov 30, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $68 M offered; $49 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Leuchtenberger · Executive Officer, Director
  • Robert Conerly · Executive Officer
  • C. Boyd H. Clarke · Director
  • Cecilia S. Gonzalo · Director
  • George M. Milne, Jr. · Director
  • Harry H. Penner, Jr. · Director
  • Jonathan S. Leff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Conerly, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 30, 2012. Read the notice at the SEC.

equitySEC
Jan 2011$6 MNo. 2$2 to $10 million

RIB X Pharmaceuticals Inc.: Raise no. 2, Jan 2011

Investors in this round

11 investors had bought by the notice of Jan 28, 2011: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $22 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Leuchtenberger · Executive Officer, Director
  • Robert Conerly · Executive Officer
  • C. Boyd H. Clarke · Director
  • Cecilia Gonzalo · Director
  • George H. Milne · Director
  • Harry H. Penner, Jr. · Director
  • Jonathan Leff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Conerly, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 28, 2011. Read the notice at the SEC.

debt, optionsSEC
May 2010$6 MNo. 1$2 to $10 million

RIB X Pharmaceuticals Inc.: Raise no. 1, May 2010

Investors in this round

16 investors had bought by the notice of Jun 10, 2010: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $15 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Leuchtenberger · Executive Officer, Director
  • Robert Conerly · Executive Officer, Director
  • C. Boyd H. Clarke · Director
  • Cecilia Gonzalo · Director
  • Harry H. Penner, Jr. · Director
  • Jonathan H. Fleming · Director
  • Jonathan Leff · Director
  • Peter H. Greenleaf · Director
  • Raymond H. Whitaker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Conerly, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • RIB X Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2012).

    SEC Form D · Nov 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2012

That is all the official record says: RIB X Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of RIB X Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by RIB X Pharmaceuticals Inc.
NameRoleNamed in
Mark LeuchtenbergerExecutive officerNov 2012
Robert ConerlyExecutive officerNov 2012
C. Boyd H. ClarkeDirectorNov 2012
Cecilia S. GonzaloDirectorNov 2012
George M. Milne, Jr.DirectorNov 2012
Harry H. Penner, Jr.DirectorNov 2012
Jonathan S. LeffDirectorNov 2012
Mark LeuchtenbergerDirectorNov 2012
Cecilia GonzaloDirectorJan 2011
George H. MilneDirectorJan 2011
Jonathan LeffDirectorJan 2011
Jonathan H. FlemingDirectorJun 2010
Peter H. GreenleafDirectorJun 2010
Raymond H. WhitakerDirectorJun 2010
Robert ConerlyDirectorJun 2010